Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 284-293

  Almahmoud, Iyad ^a,b   Kay, Elisabeth ^a,b   Schneider, Dominique ^a,b   Maurin, Max ^a,b,c  

^a UNIV GRENOBLE ALPES   (France)

^b CNRS   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Evolution; Legionella pneumophila; Mutations; Resistance mechanisms

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXYCYCLINE; ERYTHROMYCIN; GLYCINE; ISOLEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SERINE; THREONINE; TYROSINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; CONTROLLED STUDY; GENE MUTATION; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NONHUMAN;

EID: 67650751595     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp173     Document Type: Article

References (54)

1. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62 Suppl. 1: I1-9.
2. Kresse H, Belsey M, Rovini H. The antibacterial drugs market. Nat Rev Drug Discov 2007; 6: 19-20.
3. Linder JA, Huang ES, Steinman MA et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118: 259-68.
4. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl. 2: S120-6.
5. Ruiz J. Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51: 1109-17.
6. Drlica K, Malik M. Fluoroquinolones: Action and resistance. Curr Top Med Chem 2003; 3: 249-82.
7. Laferl H, Fournier PE, Seiberl G et al. Murine typhus poorly responsive to ciprofloxacin: A case report. J Travel Med 2002; 9: 103-4.
8. Raoult D, Houpikian P, Tissot Dupont H et al. Treatment of Q fever endocarditis: Comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999; 159: 167-73.
9. Somani J, Bhullar VB, Workowski KA et al. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181: 1421-7.
10. Kurz RW, Graninger W, Egger TP et al. Failure of treatment of legionella pneumonia with ciprofloxacin. J Antimicrob Chemother 1988; 22: 389-91.
11. Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12: 137-55.
12. Al Dahouk S, Hagen RM, Nockler K et al. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy 2005; 51: 352-6.
13. Shkarupeta MM, Lazarev VN, Akopian TA et al. Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy. Bull Exp Biol Med 2007; 143: 713-7.
14. Yokoi S, Yasuda M, Ito S et al. Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis. J Infect Chemother 2004; 10: 262-7.
15. Musso D, Drancourt M, Osscini S et al. Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii. Antimicrob Agents Chemother 1996; 40: 870-3.
16. Spyridaki I, Psaroulaki A, Kokkinakis E et al. Mechanisms of resistance to fluoroquinolones in Coxiella burnetii. J Antimicrob Chemother 2002; 49: 379-82.
17. Dessus-Babus S, Bébéar CM, Charron A et al. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42 2474-81.
18. Biswas S, Raoult D, Rolain JM. Molecular mechanisms of resistance to antibiotics in Bartonella bacilliformis. J Antimicrob Chemother 2007; 59: 1065-70.
19. Turkmani A, Psaroulaki A, Christidou A et al. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA. Int J Antimicrob Agents 2008; 32: 227-32.
20. Fraser DW, Tsai TR, Orenstein W et al. Legionnaire's disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297 1189-97.
21. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: Time for a change. Ann Intern Med 1998; 129: 328-30.
22. Kurz RW, Graninger W, Egger TP et al. Failure of treatment of Legionella pneumonia with ciprofloxacin. J Antimicrob Chemother 1988; 22: 389-91.
23. O'Reilly KM, Urban MA, Barriero T et al. Persistent culture-positive Legionella infection in an immunocompromised host. Clin Infect Dis 2005; 40: 87-9.
24. Tan JS, File TM, DiPersio JR et al. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. Clin Infect Dis 2001; 32: 1562-6.
25. Atlas RM. Legionella: From environmental habitats to disease pathology, detection and control. Environ Microbiol 1999; 1: 283-93.
26. Jonas D, Engels I, Hartung D et al. Development and mechanism of fluoroquinolone resistance in Legionella pneumophila. J Antimicrob Chemother 2003; 51: 275-80.
27. Linde H, Morgenroth K, Barabas S et al. The amino acid substitution Asp87Tyr in GyrA of Legionella pneumophila Sg 1 is associated with elevated MICs to nalidixic acid but not to ciprofloxacin or moxifloxacin in vitro. Intern J Med Microbiol 2002; 292: 137-8.
28. Morgan-Linnell SK, Zechiedrich L. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2007; 51: 4205-8.
29. Komp Lindgren P, Marcusson LL, Sandvang D et al. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2343-51.
30. Heisig P, Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91.
31. Komp Lindgren P, Karlsson A, Hugues D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-32.
32. Li X, Mariano N, Rahal JJ et al. Quinolone-resistant Haemophilus influenzae: Determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2004; 48: 4460-2.
33. Feeley JC, Gibson RJ, Gorman GW et al. Charcoal-yeast extract agar: Primary isolation medium for Legionella pneumophila. J Clin Microbiol 1979; 10: 437-41.
34. Gabay JE, Horwitz MA. Isolation and characterization of the cytoplasmic and outer membrane of the Legionnaires' disease bacterium (Legionella pneumophila). J Exp Med 1985; 161: 409-22.
35. Lee Y-J, Cho J-K, Kim K-S et al. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken J Microbiol 2005; 43: 391-7.
36. Cattoir V, Lesprit P, Lascols C et al. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid. J Antimicrob Chemother 2006; 58: 1054-7.
37. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-85.
38. Kumagai Y, Kato JI, Hoshino K et al. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother 1996; 40: 710-4.
39. Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents and Chemother 1991; 35: 1647-50.
40. Gensberg K, Jin YF, Piddock LJV. A novel gyrB mutation in a quinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol Lett 1995; 132: 57-60.
41. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: Recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
42. Ito H, Yoshida H, Bogaki-Shonai M et al. Quinolone-resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38: 2014-23.
43. Weinreich DM, Watson RA, Chao L. Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. Evolution 2005; 59: 1165-74.
44. Weinreich DM, Delaney NF, DePristo MA et al. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 2006; 312: 111-4.
45. Roig J, Rello J. Legionnaires' disease: A rational approach to therapy. J Antimicrob Chemother 2003; 51: 1119-29.
46. Edelstein PH, Edelstein MA, Ren J et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40: 314-9.
47. Jonas D, Engels I, Friedhoff C et al. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47: 147-52.
48. Saito A, Sawatari K, Fukuda Y et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985; 28: 15-20.
49. Stout JE, Arnold B, Yu VL. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998; 41: 289-91.
50. Schindel C, Siepmann U, Han S et al. Persistent Legionella infection in a patient after bone marrow transplantation. J Clin Microbiol 2000; 38: 4294-5.
51. Moffie BG, Mouton RP. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J Antimicrob Chemother 1988; 22: 457-62.
52. Rantakokko-Jalava K, Jalava J. Development of conventional and real-time PCR assays for detection of Legionella DNA in respiratory specimens. J Clin Microbiol 2001; 39: 2904-10.
53. D'Costa VM, McGrann KM, Hugues DW et al. Sampling the antibiotic resistome. Science 2006; 311: 374-7.
54. Waters B, Davies J. Amino acid variation in the GyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics. Antimicrob Agents Chemother 1997; 41: 2766-9.